ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

1.920 -0.180 (-8.57%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 20, 2026 Add to My Watchlist

Price and Volume

Volume	488,010
Open	2.120
Bid (Size)	1.800 (4,500)
Ask (Size)	1.960 (300)
Prev. Close	2.100
Today's Range	1.910 - 2.126
52wk Range	0.4440 - 2.660
Shares Outstanding	40,869,135
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

June 30, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

June 30, 2026

From ALX Oncology

Via GlobeNewswire

Performance

YTD	+67.0%	+67.0%
1 Month	+17.8%	+17.8%
3 Month	+9.7%	+9.7%
6 Month	+45.5%	+45.5%
1 Year	+300.0%	+300.0%

More News

ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs ↗

June 03, 2026

Via MarketBeat

ALX Oncology (ALXO) Q1 2026 Earnings Transcript ↗

June 01, 2026

Via The Motley Fool

ALX Oncology Holdings Inc (NASDAQ:ALXO) Beats Q1 Estimates and Unveils Promising Breast Cancer Data ↗

May 08, 2026

Via Chartmill

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

June 01, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 08, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

May 07, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology (NASDAQ:ALXO) Extends Cash Runway to 2028, Refines Evorpacept Strategy After Q4 Earnings ↗

February 27, 2026

Via Chartmill

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

April 30, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

April 13, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology (ALXO) Q4 2025 Earnings Transcript ↗

February 27, 2026

Via The Motley Fool

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 27, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

February 19, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

February 19, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology Announces Pricing of Underwritten Offering

January 30, 2026

From ALX Oncology

Via GlobeNewswire

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

January 30, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 08, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

January 08, 2026

From ALX Oncology

Via GlobeNewswire

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

December 07, 2025

From ALX Oncology

Via GlobeNewswire

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

November 19, 2025

Via FinancialNewsMedia

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

November 19, 2025

From FN Media Group LLC

Via GlobeNewswire

ALX Oncology to Present at Upcoming Investor Conferences

November 18, 2025

From ALX Oncology

Via GlobeNewswire

ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Wider-Than-Expected Q3 2025 Loss Amid Promising Clinical Data ↗

November 07, 2025

Via Chartmill

Frequently Asked Questions

Is ALX Oncology Holdings Inc. - Common Stock publicly traded?

Yes, ALX Oncology Holdings Inc. - Common Stock is publicly traded.

What exchange does ALX Oncology Holdings Inc. - Common Stock trade on?

ALX Oncology Holdings Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ALX Oncology Holdings Inc. - Common Stock?

The ticker symbol for ALX Oncology Holdings Inc. - Common Stock is ALXO on the Nasdaq Stock Market

What is the current price of ALX Oncology Holdings Inc. - Common Stock?

The current price of ALX Oncology Holdings Inc. - Common Stock is 1.920

When was ALX Oncology Holdings Inc. - Common Stock last traded?

The last trade of ALX Oncology Holdings Inc. - Common Stock was at 07/20/26 04:00 PM ET

What is the market capitalization of ALX Oncology Holdings Inc. - Common Stock?

The market capitalization of ALX Oncology Holdings Inc. - Common Stock is 78.47M

How many shares of ALX Oncology Holdings Inc. - Common Stock are outstanding?

ALX Oncology Holdings Inc. - Common Stock has 78M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.